This large study adds to the evidence that pancreatic cancer is more common in people who eat too much fat, particularly saturated fat
Josephine Querido, Cancer Research UK
Sunday, 28 June 2009
Sunday, 21 June 2009
Thursday, 18 June 2009
Where did the story come from?
What kind of scientific study was this?
What were the results of the study?
What interpretations did the researchers draw from these results?
What does the NHS Knowledge Service make of this study?
Links To The Headlines
Links To Science
Obesity and hunger: The problem with food
Monday, 1 June 2009
Press Release - Ateronon 1 June 2009 - A breakthrough for heart health – tomato pill prevents the
We're urging caution over claims by scientists that a natural supplement made from tomatoes, taken daily, can stave off heart disease and strokes.
The scientists say that a 'tomato pill' containing an active ingredient from the Mediterranean diet - lycopene - can block "bad" LDL cholesterol that can clog the arteries.
Ateronon, made by a biotechnology company attached to Cambridge University, is being launched as a dietary supplement and is to be be sold on the high street.
But in response to the launch, at the 2009 British Cardiac Society conference, Professor Peter Weissberg, Medical Director at the British Heart Foundation said:
"As always, we caution people to wait for any new drug or modified ‘natural’ product to be clinically proven to offer benefits before taking it. It will take some time, and several clinical trials, to provide such evidence for Ateronon.
"In the meantime, our advice to heart disease patients or those at high risk is to rely on proven medications prescribed by their doctor, and aim to get the benefits of a Mediterranean diet by eating plenty of fresh fruit and veg.
"We need to be clear in this instance, that the British Heart Foundation supported some of the basic science at Cambridge University underpinning the development of this product over a decade ago and, as such, could benefit from its commercialisation."
"But until they have done proper clinical trials there is no proof that it will make you live longer and healthier. "The pill costs more than £1 a day - and you can buy a lot of tomatoes for that. They probably taste better too."
ATERONON™ is a new ‘one-a-day’ natural supplement of 7mg patented, highly bioavailable lycopene (wikipedia).
ATERONON™, through clinical studies, has been shown to significantly reduce the oxidation of LDL cholesterol, recognised as one of the principal causes of astherosclerotic plaque formation, and may provide important information towards the reduced risk of heart attack and stroke.
As a natural formulation, it is possible to take ATERONON™ alongside prescribed medication and other supplements.*
ATERONON™ is designed to be taken on an on-going basis in order to help maintain bioavailable levels of lycopene in the body that will continue to inhibit the oxidation of LDL cholesterol, which helps reduce the risk of plaque build-up in the arteries.
It is a natural product and is not known to have any side effects. It is not suitable for those with allergies to tomato, whey protein or soy.
- More than half of all heart attacks and three quarters of all strokes occur in people who do not have an elevated cholesterol level
- Statins reduce the overall level of LDL but they do not prevent oxidative damage and atheromatous plaque formation
- The Mediterranean diet is associated with increased protection against heart attack and stroke
- ATERONON™ is based on one of the main active components of the Mediterranean diet, lycopene, which has been shown to reduce the oxidation of LDL dramatically
- ATERONON™ delivers lycopene in a form that can reach optimum sustainable levels in the body with a once-daily capsule
- ATERONON™ is a food grade product that has not been associated with any adverse effects in either healthy individuals or patients with cardiovascular disease alike
- ATERONON™ is not suitable for individuals with food allergies to, or intolerance of, tomatoes, milk and soya derivatives
- The ability of ATERONON™ to help inhibit LDL oxidation, recognised as a key step in the process of atherosclerosis offers new information in the work to reduce the risks of heart attack and stroke and, possibly, other atherosclerotic plaque-based conditions such as dementia and age-related macular degeneration.
ATERONON™ has been developed by Cambridge Theranostics, working with innovations originally identified by food company Nestle. Cambridge Theranostics is a bio-technology spin-out company from Cambridge University, originally funded by the British Heart Foundation.
ATERONON™ is produced to GMP standards in Milan, Italy.
reposted from: http://www.ateronon.com/About-Ateronon/Clinically-Proven.aspx
However, statins do not prevent the oxidation of LDL and half of all heart attacks and strokes occur in people who do not have an elevated cholesterol level.
Ateronon™, a recently developed product of a highly bio-available form of lycopene, can reduce lipoprotein oxidation by up to 90% in older individuals with active atherogenesis within two months of commencing its administration.
ATERONON™ capsules given daily to older individuals with heart disease (mean age 61, range 40-70) doubled plasma lycopene levels in two weeks from 0.26 to 0.52µmol/L. To reduce the risk of atherosclerosis it is necessary to achieve plasma concentrations of the antioxidant lycopene of at least 0.2µmol/L, with an increasing trend in improvement from 0.2 to 0.6µmol/L.
"Lycopene, when delivered to the body, prevents oxidative damage of plasma lipoproteins, which reduces the build up of arterial plaques and reduces the risk of heart disease, stroke and other clinical complications of atherosclerosis.”